Proprietary technologies
Many capabilities are required to develop and commercialise an inhaled pharmaceutical successfully. The active pharmaceutical ingredient (API) needs to be formulated so that it can be inhaled and reach the targeted area of the lungs. A high degree of control over particle size, chemical and particle stability is required. An inhaler device is needed in which the newly formulated drug can be stored, protected from moisture, and which enables the formulation to be inhaled on demand. Filling and packaging the formulation in reservoirs or blisters must be considered early in the development programme. All of these considerations need eventually to be addressed at an industrial scale.
Vectura has the complete range of device and formulation technologies to take an API and deliver a finished inhaled pharmaceutical product and has proven its ability to industrialise its products for marketing purposes.
Since Vectura’s devices are proprietary, any products developed using these technologies are provided a high degree of intellectual property protection as well as the ability to be adapted for specific product requirements and unique branding purposes.
